ASCO 2018 | Updated safety & durability results for CAR-T lisocabtagene maraleucel in NHL

Jeremy Abramson

Jeremy Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses updated results from the TRANSCEND-NHL-001 trial (NCT02631044) of the CAR T-cell product lisocabtagene maraleucel for the treatment of relapsed/refractory B-cell Non-Hodgkin lymphoma. Prof. Abramsom highlights the very promising results, including respose rates and durability. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video